Compare Intuitive Machines (LUNR) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Machines vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Intuitive Machines trades at $10.79 (market cap $1.97B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Intuitive Machines is far larger — about 2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Intuitive Machines nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Machines for 7 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LUNR | MRVI | |
|---|---|---|
Market Cap | $1.97B | $972.90M |
Volume | 6,024,737 | 4,325,710 |
Sector | Industrials | Health |
52-Week High | $45.70 | $9.00 |
52-Week Low | $8.05 | $2.83 |
Typical Hold Time | 7 Days | 0 Days |
Enterprise Value | $2.04B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Machines (LUNR) trades at $12.18, down 5.29% on the day, reflecting a bearish technical trend. The company is in a high-growth phase, with revenue projected to surge from $207 million in 2025 to $481 million in 2026, but it remains deeply unprofitable with a net loss margin of -27.1%. Recent news highlights its strategic position in lunar infrastructure and satellite manufacturing, supported by NASA contracts, though the stock faces pressure from broader sector weakness.
The investment case hinges on execution of its growth strategy amid significant cash burn. Analyst consensus is strongly bullish with an $31.33 price target, but high execution risk and persistent losses present a speculative opportunity. Key risks include dependence on government contracts and intense competition in the space sector.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Machines
Intuitive Machines provides lunar access, data, and infrastructure services. Its capabilities include lunar landers, communications systems, and technologies designed to support missions to the Moon.
Read more on LUNR →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
